Differentiation of entamoeba histolytica/entamoeba dispar by PCR and their correlation with humoral and cellular immunity in individuals with clinical variants of amoebiasis. by Sánchez-Guillén, María Del Carmen et al.
DIFFERENTIATION OF ENTAMOEBA HISTOLYTICA/ENTAMOEBA DISPAR BY PCR
AND THEIR CORRELATION WITH HUMORAL AND CELLULAR IMMUNITY IN
INDIVIDUALS WITH CLINICAL VARIANTS OF AMOEBIASIS
MARI´A DEL CARMEN SA´NCHEZ-GUILLE´N, RICARDO PE´REZ-FUENTES, HILDA SALGADO-ROSAS,
ALEJANDRO RUIZ-ARGU¨ELLES, JOHN ACKERS, ABDIRASHID SHIRE, AND PATRICIA TALAMA´S-ROHANA
Laboratorio de Parasitología, Centro de Investigación Biomédica de Oriente, IMSS, Puebla, México; Facultad de Medicina, BUAP,
Puebla, México; Laboratorios Clínicos de Puebla, Puebla, México; London School of Hygiene and Tropical Medicine, London, U.K.;
Departamento de Patología Experimental, CINVESTAV-IPN, México, D.F., México
Abstract. To correlate a particular state of immunity with Entamoeba spp., we used colorimetric PCR to differentiate
E. histolytica from E. dispar in individuals with amoebiasis and to associate its presence with the clinical profile, including
humoral and cellular immune responses to E. histolytica. Our results showed high levels of antibody in acute amoebiasis
and elevation of IL-4 production, a cytokine related to Th2 profile, associated with E. histolytica. In chronic amoebiasis,
even with anti-E. histolytica seropositivity, intestinal symptoms were associated with E. dispar in all the cases, without
differences in level of antibodies, BTI, CD4+/CD8+ ratio, INF-, and IL-4. Among asymptomatic carriers, E. dispar was
more frequently found; however, identification of E. histolytica in two asymptomatic carriers associated with high levels
of INF-, a cytokine related to Th1 profile, demonstrate the importance of making specific diagnosis of Entamoeba spp.,
to establish the clinical and epidemiological behavior in both intestinal and extra-intestinal amoebiasis.
INTRODUCTION
Amoebiasis continues to be a significant world-wide health
problem. It has been estimated that 500 million individuals
are infected with the causal agent Entamoeba histolytica and
of these, 40 million would develop invasive disease, causing at
least 100,000 deaths a year, most of these are secondary to the
extra-intestinal complications like hepatic abscess.1,2
In accordance with epidemic studies carried out in different
parts of the world, the seroprevalence found in some com-
munities of developing countries ranges from 5% to 55%.3–7
In 1988, the National Serologic Survey in México showed a
seroprevalence of 8.41% for the whole country, highlighting
the State of Puebla with 14.98%.8
The epidemiological analysis of the relationship between
the prevalence of infected individuals and the number of
cases with invasive amoebiasis made by E. Brumpt in 1925,9
and confirmed by Walsh in 1986,1 showed that the disease is
present in approximately 10% of people with cysts of E. his-
tolytica in feces. This fact suggested the existence of two spe-
cies of E. histolytica to explain the epidemic behavior of
amoebiasis in the world.10,11
Studies during the last 30 years have confirmed the exis-
tence of two morphologically indistinguishable species of En-
tamoeba. E. histolytica, the pathogenic species and E. dispar,
the non-pathogenic species. Recent acceptance by the scien-
tific community of these two different species has had an
important impact on our understanding of clinical amoebia-
sis.2
Diverse methods exist to differentiate pathogenicity and
virulence from Entamoeba spp., most of them requiring the
isolation and culturing of the microrganism.12–16 Recently,
Aguirre and others reported the amplification by PCR of
specific segments of DNA, and the use of specific probes to
allow for the differential diagnosis of pathogenic and non-
pathogenic Entamoeba spp. in feces.17
Usually, the identification of specific antibodies against an-
tigens of E. histolytica does not correlate with resistance to
the infection or with protective immunity.18 However, detec-
tion of seric antibodies is a useful procedure in the diagnosis
of invasive extra-intestinal amoebiasis, but not in the intesti-
nal forms, where it is not feasible to distinguish asymptomatic
carriers from patients with amoebic dysentery, especially in
endemic areas where antibody titer is not enough to diagnose
acute intestinal amoebiasis.19
Mosmann and Coffman have shown that specific Th1/Th2
cytokine profiles depend on the subpopulation of CD4+ T
lymphocytes.20 These subpopulations participate in the regu-
lation of the immune response induced by infection with
Leishmania spp. in animal models,21 and the data has been
confirmed with other pathogenic agents.22–24 During invasive
amoebiasis, decrease of CD4+ cells, increase of CD8+ cells, as
well as decrease in in vitro proliferation of T lymphocytes
against amoebic antigens have been described.25 Also an im-
munosupressive state has been observed on delayed cutane-
ous hypersensitivity against amoebic antigens. On the other
hand, high levels of Interferon- (IFN-) (profile Th1) are
associated with a higher cytotoxic effect of macrophages
against trophozoites of E. histolytica.26,27 Additionally, stud-
ies in a murine model suggest that the induction of the Th1/
Th2 profile is dependent on specific peptides of E. his-
tolytica.28
The asymptomatic/symptomatic clinical state in individuals
infected with E. histolytica could be explained by the combi-
nation of cytokines that reflect the Th1/Th2 profile and the
recent acceptance of the two different, pathogenic and non-
pathogenic species. In the present work we use colorimetric
PCR to differentiate E. histolytica from E. dispar, to establish
correlation between the humoral and cellular immune re-
sponses in individuals with clinical variants of amoebiasis
coming from an urban community of the state of Puebla,
México.
MATERIALS AND METHODS
Study population. The study was carried out in an urban
community of the municipality of Puebla, located in the
southeast region of México, at an altitude of 1,800 meters and
surrounded by high volcanoes. Human population is about 2
million; 60% of them living in an appropriate environment for
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the transmission and development of the disease. The esti-
mated seroprevalence in the state, according to the 1988 Na-
tional Serologic Survey, was 14.98%.8
Study subjects. Informed consent was obtained from all hu-
mans participants and from parents or legal guardians of mi-
nors. The study group was composed of 47 individuals. The
diagnosis of the clinical variant of amoebiasis was accom-
plished by a meticulous clinical study together with parasi-
tolological examination.
The cohort of Acute Intestinal Amoebiasis (AIA) (eleven
patients), was clinically diagnosed with colic, tenesmus, tro-
phozoites of Entamoeba spp., mucus and/or blood in feces, as
well as anti-amoebic antibodies by ELISA (positive serol-
ogy). Thirteen individuals formed the cohort of Chronic In-
testinal Amoebiasis (CIA), showing positive serology, pres-
ence of cysts of E. histolytica/dispar, and symptoms of alter-
nating diarrhea-constipation with manifestations of
abdominal distension, colic, and tenesmus. Thirteen subjects
formed the cohort of Asymptomatic Carriers (AC) with posi-
tive serology, shedding of cysts of Entamoeba spp., and ab-
sence of clinical evidence of disease. The Control Group
(CG) was formed by 10 asymptomatic individuals with ab-
sence of parasite cysts in feces verified by PCR. Blood
samples were collected and serum fractions stored at −20°C
until used.
Parasitological diagnosis. The morphologic identification
of the parasite was carried out by coproparasitoscopic analy-
sis employing a direct method in cases of semi-liquid or liquid
feces, or by the modified Ritchie’s assay in cases of formed
feces.29 Samples containing cysts or trophozoites of E. his-
tolytica and/or E. dispar, were diluted in PBS, aliquoted, and
stored at −20°C until used. The molecular diagnosis was made
by Colorimetric PCR as described.17,30 The DNA from E.
histolyticaHM1-IMSS and from E. dispar clone 5331 was used
as a positive control.
Detection of antiamoebic antibodies in human sera by
ELISA. This procedure was performed as described,32 using
10 g/mL of E. histolytica total extract and human sera at a
1:100 dilution. The cut off value for the ELISA test was an
O.D of 0.032 ± 0.009.
Isolation of peripheral blood lymphocytes. Lymphocytes
were purified from peripheral blood by the Ficoll-Hypaque
(Sigma, St. Louis, MO) method.33 Cell viability was verified
by the trypan blue exclusion test. Cells adjusted to 3.6 × 106 in
1.8 mL of RPMI-1640 culture medium were used for cell
proliferation, and 2 × 106 cells in 200 L of diluent for T
CD4+/CD8+ determination.
T cell proliferation assays. Lymphocytes (220 × 103) were
cultivated in a 96 well plate, stimulated with phytohemaglu-
tinin (PHA) (1:250), and amoebic total extract28 (100 g/mL)
at 37°C for 5 days. Proliferation of T cells against antigen or
PHA was measured by [3H]-thymidine (1 Ci per well, 6.7
Ci/mmol; Amersham) incorporation after 18 hr. Cells were
harvested on glass fiber filters, and incorporated radioactivity
was measured by liquid scintillation in a Beckman Instrument
(LS5801). Blast transformation index (BTI) was obtained ac-
cording to Savanat, 197334: BTI  log cpm stimulated cells/
log cpm control cells.
CD4+/CD8+ ratio. Determination of CD4+/CD8+ ratio
was carried out by flow cytometry using Simultest CD4+/
CD8+ kit (Becton-DickinsonMR). Briefly, 1 × 106 lympho-
cytes in 100 L were mixed with 20 L of the respective
monoclonal antibody, incubated 15 min at room temperature,
washed with PBS/BSA, and centrifuged 10 min at 2,000 × g.
The pellet was resuspended in 2% p-formaldehyde and the
cell suspension read in a flow cytometer. Reference values for
normal individuals ranges from 0.6 to 2.2.
Cytokine assays. For quantitative determination of IL-4
and INF- cytokines, ELISA kits (Genzyme Diagnostics, Pre-
dicta) were used. Supernatant from lymphocyte cultures was
incubated with mouse monoclonal antibodies against human
IL-4 or INF- adsorbed on the bottom of 96 well plates, and
then 50 L of the sample diluter were added per 50 L of
sample. Biotinylated IgGs against IL-4 or INF- were incu-
bated for 1 hr at room temperature to perform a sandwich
ELISA. After 5 washes, 100 L of peroxidase labeled strepta-
vidin was added and the plate incubated for 15 min at 37°C.
After 5 washes, 100 L of substrate were added, incubated at
room temperature (18–24°C) for 20 min, then 100 L of 1 N
H2SO4 were added to each well to change the color from blue
to yellow. Plates were read in a spectrophotometer at 450 nm.
Statistical analysis. The statistical evaluation was carried
out using the Mann-Whitney U-test . Values of P < 0.05 were
considered statistically significant. The results in Table 2 are
presented as ± one standard deviation. The results in Figure
1–3 are presented as mean ± SE.
RESULTS
Study population. Forty-seven individuals were included in
a longitudinal and prospective study (cohorts study). All of
them were evaluated by parasitological, clinical, and immu-
nological criteria at the moment of diagnosis, at one month,
and at three months after diagnosis. Due to ethical criteria,
the control group (CG) was evaluated only at the moment of
diagnosis to have references values. Twenty-two were men
(46.8%) and 25 women (53.1%). Age analysis showed that
95% of the individuals were between 2 and 40 years old.
Selection according to the clinical variant showed that 11
(23%) individuals corresponded to the cohort of AIA, 13
(28%) to the cohort of CIA, 13 (28%) to the cohort of AC,
and 10 (21%) to the CG.
The clinical characterization at the moment of diagnosis
from these cohorts showed: diarrhea with mucus and blood
present in 5 cases of AIA; feces with mucus in 6 cases of AIA
and 3 cases of CIA; colic in 9 cases of AIA and 10 cases of
CIA; abdominal distension in 8 cases of AIA and 2 cases of
CIA; tenesmus in 11 cases of AIA and 5 cases of CIA; con-
stipation in 11 cases of CIA. After diagnosis, all the patients
were treated and in each case the physician administered spe-
cific treatment according to the hospital regulations.
Identification of E. histolytica/E. dispar by colorimetric
PCR. Control Group samples (10 out of 47) were negative by
coproparasitoscopic analysis (CPS), and also by PCR. From
the remaining 37 positive samples by CPS, only 29 were posi-
tive by colorimetric PCR for E. histolytica and/or E. dispar
(Table 1). Based on PCR results, the clinically defined co-
horts were further divided into subsets according to the pres-
ence or absence of E. histolytica/E. dispar (Table 2).
Immunological parameters.Antibody levels, BTI, CD4+/
CD8+ ratio, IL-4, and INF- levels for the clinically defined
cohorts, and the PCR defined subsets were determined at
diagnosis time, and at one and three months after diagnosis.
Distribution of anti-Entamoeba spp. antibodies.A signifi-
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cant difference was observed between AIA and CG at the
time of diagnosis and at one month (P < 0.05), but not three
months later (Figure 1). In the cohort of AIA, the E. his-
tolytica subset was seropositive at the time of diagnosis; this
titer decreased at one month but three months later it was
even lower than that of CG (Table 2). With respect to the E.
dispar subset, it presented low titers at the time of diagnosis
with respect to CG (Table 2) but it increased at one month
after diagnosis (0.137 ± 0.114).
Blast Transformation Index (BTI). The results obtained
with the groups (AIA, CIA, AC) or the subsets (PCR positive
for E. histolytica or E. dispar) did not show significant differ-
ences compared with CG (data not shown).
CD4+/CD8+ ratio. Determination of the CD4+/CD8+ ratio
at the different times did not show significant differences
among the different groups and subsets, compared with CG
(data not shown).
Interleukin-4 and Interferon- (Th1/Th2 profile). Th1/Th2
profile was defined by INF- and IL-4 serum levels. IL-4
levels at the time of diagnosis and at three months were sig-
nificantly different between CG and AIA (Figure 2), and also
in the subset proven to be infected with E. histolytica (P <
0.05) (Table 2). The two members of the AIA subset infected
with E. dispar did not show significantly raised levels of IL-4
(Table 2). Levels of INF- in two individuals from the AC
cohort infected with E. histolytica, were significantly higher,
both at diagnosis time and at three months compared with
CG (P < 0.05) (Figure 3); the nine AC patients infected with
E. dispar were not significantly different from CG (Table 2).
Neither AIA cohort (Figure 3) nor those individuals from the
subset infected with E. histolytica (Table 2), showed signifi-
cant differences in serum INF- levels compared with CG.
DISCUSSION
The recognition of E. histolytica and E. dispar as different
species, has provided important insights into the epidemic
behavior of amoebiasis in the world,1 and has had important
epidemiological and clinical implications.10 The existence of
asymptomatic carriers of E. histolytica,34–38 has raised doubts
about the proportion of individuals infected who are truly at
risk of invasive amoebiasis, and questions the human host
factors, that favors this apparently commensal-like relation-
ship with E. histolytica.
A mixture of symptomatic and asymptomatic cases is fre-
quently observed in infections by pathogenic agents. Al-
though some elements of the microorganisms such as viru-
lence, inoculum size, exhibition routes, etc., affect the subse-
quent manifestations of the infection, undoubtedly host
factors contribute in a substantial way in the outcome of the
host-parasite relationship.39 Among these factors, the CD4+/
CD8+ ratio and a specific cytokine profile, characteristic of
subpopulations of CD4+ T lymphocytes, seem to play an im-
portant role.21,40 In the present study, we examined the im-
portance of humoral and cellular immunity in the outcome of
the relationship between the host and E. histolytica/E. dispar
in individuals with clinical variants of amoebiasis.
The population studied was young (80% younger than 20
years old), and came from urban and suburban areas of the
municipality of Puebla, México, an entity of 2 million inhab-
itants. The seroprevalence of 14.98% reported for the state of
Puebla is relatively high compared with other parts of
México8 but comparable to those reported for other cities in
developing countries such as South-Africa, Brazil, India, and
Bangladesh.41–43
Infection with E. histolytica/E. dispar in endemic areas fre-
quently coexists with other protozoa and helminths35; there-
fore, to avoid the interpretation biases observed in previous
investigations41 we included in the study only those cases in-
fected with E. histolytica/E. dispar. By following them during
three months, beginning at the moment of diagnosis, we were
able to evaluate the behavior of different forms of the disease
over time. The cohort of AIA comprised the cases of appar-
ent amoebic dysentery referred from a suburban clinic over a
2-year period. The parasitological diagnosis consisted on the
finding of trophozoites associated with the presence of mucus
and /or blood, a widely used method effective in the diagnosis
of AIA,44 in accordance with recommendations of the World
Health Organization (1997).2 Parasites were later confirmed
as E. histolytica by colorimetric PCR standardized using
spiked samples.17,30 This procedure is apparently 100% spe-
cific but not 100% sensitive when applied to stored fecal
samples (Shire and Ackers, unpublished observations). Thus,
whereas a positive result confirms the diagnosis, a negative
one does not exclude it; therefore, an adequate sample stor-
age and conservation procedure is of great importance. Based
on PCR results, the clinically defined cohorts were further
subdivided.
It should be noted that even before applying PCR, in 90%
of the cases the doctor’s clinical suspicion of amoebic dysen-
tery was not corroborated, demonstrating a clinical over-
diagnosis of AIA. It has been reported that, patients diag-
nosed with amoebic dysentery are frequently infected with
Shigella dysenteriae and Shigella flexneri,45 or other different
pathogens including enteroinvasive Escherichia coli, Salmo-
nella spp., and Campylobacter jejuni.46
The production of antibodies is the main immunological
manifestation of invasive amoebiasis in humans, although its
presence is not associated with resistance to infection or with
protective immunity.18 Their utility is accepted in cases of
extra intestinal invasive amoebiasis, but not in the intestinal
form.18,47 In contrast with reports from other groups, in this
study the cohort of AIA showed significantly higher antibody
titers compared with those in the cohorts of CIA, AC, and
CG, both at the moment of diagnosis and one month later;
values had returned to control levels by three months. The
humoral immune response observed with the different groups
was obtained using total extract of E. histolytica trophozoites
as the antigen. The possibility to use E. dispar instead of E.
histolytica as the antigen, for those cases where PCR was
positive for E. dispar, may change the results obtained so far.
TABLE 1
Determination of Entamoeba histolytica/E. dispar by colorimetric
PCR in individuals with clinical variants of amoebiasis
Clinical variant
*PCR +
E.h.
**PCR +
E.d. Negative Total
Acute intestinal amoebiasis 7 2 2 11
Chronic intestinal amoebiasis 0 9 4 13
Asymptomatic carriers 2 9 2 13
Control group 0 0 10 10
Total 9 20 18 47
*  Identification of Entamoeba histolytica by PCR.
**  Identifcation of Entamoeba dispar by PCR.
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Interestingly, the two patients assigned to the AIA cohort on
clinical grounds but in whom PCR demonstrated E. dispar
presented lower antibody levels compared with patients with
AIA and E. histolytica.
Regarding cell-mediated immunity the work of Savant,34
Ortiz,48 and later Salata49 observed a poor lymphocyte re-
sponse measured by BTI in circulating T lymphocytes. On the
other hand, Ganguly and others,50 demonstrated a decrease
in the number of T lymphocytes circulating in the blood of
patients with amoebic hepatic abscess. In our investigation,
the proliferation of T cells measured by BTI was low. This
differs from the results of Ortiz, Harris, Segovia, and Dia-
manstein51–54 who found a proliferative response to amoebic
antigens from lymphocytes of patients with amoebic hepatic
abscess. Moreover, Velásquez and others,55 observed prolif-
eration of peripheral blood mononuclear cells of a patient
with amoebic hepatic abscess against a 170 kDa recombinant
protein. In our case we used a total extract of E. histolytica,
and Talamás-Rohana and others,28 have reported that whole
extract might contain growth inhibiting factors, explaining in
part the results obtained by other authors,34,48,49 as well as the
low levels of blast transformation found in all the clinical
variants tested in this study, including the CG.
Salata and others49 have showed a decrease of CD4+
helper T cells and an increase of CD8+ cells in patients with
amoebic hepatic abscess. In our study the patients with inva-
sive amoebiasis showed values for the CD4+/CD8+ ratio that
were lower than those reported previously. Suppression of
the cellular immune response has been observed during the
infection by protozoan parasites, including Leishmania dono-
vani56 and Trypanosoma cruzi.23 There is also evidence that
the response of T cells is systematically suppressed during the
acute illness due to E. histolytica, as has been observed in
animal models57 and in patients with amoebic hepatic ab-
scess.49 Serum from E histolytica-infected gerbils58 and im-
mune sera from patients25 selectively suppress T cell prolif-
eration by inhibiting IL-2 and IFN- production. Previous
studies have shown that in infections caused by pathogens
that induce immunosuppression in the host, such as L. dono-
vani,56 HIV,59 and T. cruzi,23 the outcome of the relationship
could be regulated by CD4+ helper T cells with different
pattern of cytokines. Protective immunity would be associ-
ated with Th1 cells that produce INF- and IL-2, whereas Th2
cells, which produce immunosuppressive IL-4 and IL-10,
could facilitate the survival and dissemination of the parasite
generating tissue damage and the appearance of the disease.60
FIGURE 1. Anti-E. histolytica antibodies levels. Sera from each
group were evaluated by ELISA using the same serum dilution (1:
100). AIA: Acute Intestinal Amoebiasis; CIA: Chronic Intestinal
Amebiasis; AC: Asymptomatic Carrier; CG: Control Group. Serol-
ogy: Determination of anti-E. histolytica antibodies expressed as
O.D. Reference value: 0.032 ± 0.009 O.D. *, P < 0.05 (Mann-Whitney
U test, compared with CG).
FIGURE 2. Determination of seric IL-4 levels. Sera from each
group were evaluated by ELISA. AIA: Acute Intestinal Amoebiasis;
CIA: Chronic Intestinal Amoebiasis; AC: Asymptomatic Carrier;
CG: Control Group. IL-4: Seric levels expressed in pg/mL. Reference
value: 27.59 ± 2.81 pg/mL. *, P < 0.05 (Mann-Whitney U test, com-
pared with CG).
TABLE 2
Subsets according to PCR diagnosis of Entamoeba histolytica/E. dispar and its correlation with immunological parameters at the moment and
three months after diagnosis
Clinical variant
PCR
AIA CIA AC CG
Eh Ed Ed Ed Eh Neg
7 2 9 9 2 10
At moment of diagnosis
ELISA 0.149 ± 0.053* 0.069 ± 0.038 0.093 ± 0.057 0.069 ± 0.033 0.125 ± 0.033 0.073 ± 0.039
IL-4 31.56 ± 3.28* 27.76 ± 1.54 29.07 ± 3.49 29.53 ± 3.68 30.76 ± 4.05 27.72 ± 2.81
INF- 11.56 ± 3.95 8.04 ± 0.22 11.13 ± 5.85 11.40 ± 3.22 69.24 ± 16.32* 9.59 ± 1.84
At 3 months after diagnosis
ELISA 0.067 ± 0.041 0.071 ± 0.018 0.092 ± 0.043 0.082 ± 0.056 0.161 ± 0.091 0.073 ± 0.039
IL-4 31.91 ± 4.31* 28.72 ± 2.13 27.98 ± 5.44 30.53 ± 3.42 25.73 ± 2.22 27.72 ± 2.81
INF- 11.41 ± 8.36 9.58 ± 0.22 9.18 ± 0.97 9.89 ± 2.53 39.44 ± 7.35* 9.59 ± 1.84
AIA: Acute Intestinal Amoebiasis; CIA: Chronic Intestinal Amoebiasis; AC: Asymptomatic Carrier, CG: Control Group. PCR: shows the distribution by subsets of positive cases for E.
histolytica (Eh) and E. dispar (Ed) according to PCR results. ELISA: Determination of anti-E. histolytica antibodies expressed as O.D. Reference values: 0.032 ± 0.009 O.D. IL-4: Seric levels
expressed in pg/mL. Reference values: 27.59 ± 2.81 pg/mL. INF-: Seric levels expressed in pg/mL. Reference values: 9.45 pg/mL. *, P < 0.05 (Mann-Whitney U test, compared with CG).
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Recent evidence61–63 suggests an important role for IL-10,
but not for IL-4 in the Th2 response. However, as has been
proposed by others,64–67 we analyzed IL-4 and IFN- as in-
dicators of Th2 and Th1, respectively. These subpopulations
may in part explain the behavior observed in the cohorts of
patients with invasive amoebiasis and asymptomatic carriers,
considered in this study. The first group presented signifi-
cantly high levels of IL-4 (Th2 profile) at the moment of the
diagnosis, associated with the presence of the pathogenic spe-
cies E. histolytica (determined by PCR), and returning to nor-
mal levels, compared with CG, at three months post-therapy.
Regarding the cohort of untreated asymptomatic carriers, the
two individuals infected with E. histolytica presented high
levels of INF- at the moment of diagnosis, maintaining these
levels for the following three months, without alteration in the
other evaluated parameters, (levels of antibodies, BTI, CD4+/
CD8+ ratio). The nine AC patients infected with E. dispar
were not different from the CG in any immunological param-
eters and it is tempting (although the numbers are very small)
to attribute asymptomatic carriage of pathogenic E. his-
tolytica to a powerful Th1 response not seen in those who
succumbed to amoebic dysentery.
It is recognized that the chronic abdominal pain and intes-
tinal alterations are symptoms experienced by 15% of appar-
ently healthy people.68 In endemic areas such as México, this
type of condition is frequently diagnosed as chronic intestinal
amoebiasis. The etiology of CIA has not been settled and
clear-cut differences between this disease and the syndrome
of irritable bowel have not been defined.69,70 Infection in all
the cases where it could be determined in the cohort of CIA,
(characterized by abdominal distension, colicky pain, tenes-
mus, alternating diarrhea and constipation, and positive se-
rology) was due to E. dispar. Studies carried out in India,71
Panama,72 Puerto Rico,73 and Honduras74 have shown that
the typical abdominal symptoms of CIA were observed more
frequently in individuals negative for amoeba in feces.75 On
the other hand, individuals with diagnosis of CIA treated with
anti-amoebic drugs showed no improvement of symptoms.76
In this study, the identification of the non-pathogenic E.
dispar in all the cases of patients classified as CIA, does not
provide evidence for a causal relationship between infection
and symptoms. This suggests reconsideration of the existence
of this type of clinical variant of amoebiasis.
In general, our results show that invasive amoebiasis, in-
duced by the presence of E. histolytica could be partly ex-
plained by the levels of the IL-4 associated with a Th2 cyto-
kine profile. Resistance to the invasive form of the illness in
asymptomatic carriers of E. histolytica may be explained by
the high levels of IFN- associated with a Th1 cytokine pro-
file, as found in this investigation.
The identification of E. histolytica in asymptomatic carriers
demonstrates the importance of routinely making a species-
specific diagnosis in view of the participation of the asymp-
tomatic carriers of E. histolytica in the establishment and
maintenance of a pathogenic cycle of extra-intestinal amoe-
biasis in endemic regions.
To have elements to better understand the clinical-
epidemiological pattern of amoebiasis, it will be necessary to
perform longitudinal studies with a larger number of patients
to analyze all the immunological parameters which partici-
pate in the pathogenic process associated with E. histolytica
infection.
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